Back
€26M Reverse IPO
Hyris is a hi-tech company active at the intersection of AI, medtech and biotech.
Growth Capital supported Hyris’ shareholders in the negotiation of the binding agreement to sell the company to Ulisse BioMed, drafted the 5 Years Industrial Plan of the combined company and supported Hyris management in the due diligence process and in the listing activities.
In 2023, UBM Shareholders’ Meeting approved the acquisition of 100% of Hyris for €26.2M in a reverse takeover deal. After the closing, the former Hyris shareholders controlled the majority of the listed shares.
Visit website
Growth Capital supported Hyris’ shareholders in the negotiation of the binding agreement to sell the company to Ulisse BioMed, drafted the 5 Years Industrial Plan of the combined company and supported Hyris management in the due diligence process and in the listing activities.
In 2023, UBM Shareholders’ Meeting approved the acquisition of 100% of Hyris for €26.2M in a reverse takeover deal. After the closing, the former Hyris shareholders controlled the majority of the listed shares.
